Novo, Nordisk

Novo Nordisk Pledges DKK 12.1 Billion in Buybacks as Wegovy Pediatric Data and AI Research Pact Land in Busy November

Published on 11/22/2026 at 08:51 | Editorial boerse-global.de
Novo Nordisk repurchased 43.7 million B-shares for DKK 12.1 billion under its DKK 15 billion programme, alongside an AI pact and new Wegovy and CagriSema data.
Novo, Nordisk, Pledges, DKK, Billion, Buybacks, Wegovy, Pediatric, Data, Research Illustration mit AI erstellt.

Novo Nordisk has repurchased roughly 43.7 million B-shares for about DKK 12.1 billion between 4 February and 13 November, the company disclosed on 16 November, part of a buyback programme capped at DKK 15 billion.

The disclosure capped a crowded stretch of announcements spanning a new artificial-intelligence research alliance, European approval for a haemophilia treatment, late-stage obesity data and a Danish compensation payout.

AI Partnership Targets Cardiometabolic Disease

nference announced on 18 November a strategic research collaboration with Novo Nordisk. The partners intend to analyse Novo Nordisk's clinical trial data using nference's AI platform and health data network, with the aim of studying cardiometabolic disease and healthy ageing.

Shares in the Danish drugmaker fell 3.0% on Friday.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

EU Clears Frehemgo for Haemophilia A

The European Commission on 13 November granted marketing authorisation for Frehemgo for routine bleeding prevention in adults and children with haemophilia A, with or without inhibitors.

Wegovy Paediatric Trial Shows Sharp BMI Reductions

Results from the Phase III STEP Young study, reported on 16 November, showed that in the efficacy analysis the body-mass index of children aged six to under twelve with obesity fell 17.4% on semaglutide, while it rose 2.2% on placebo. Close to 80% of children treated with Wegovy recorded a BMI decline of at least 10%, a threshold no child in the placebo arm reached.

CagriSema Delivers 20.7% and 21.0% Weight Loss

Novo Nordisk on 14 November presented Phase III REDEFINE 9 data for lower doses of CagriSema. After 68 weeks, estimated mean weight loss in the efficacy analysis stood at 20.7% and 21.0% for the two dose levels, assuming all patients had stayed on treatment, against 2.0% for placebo.

Novo Nordisk at a turning point? This analysis reveals what investors need to know now.

A post-hoc analysis of REDEFINE 1, reported on 15 November, found that 67.8% of patients treated with CagriSema met the threshold for early response, having shed at least 5% of their body weight by week 8. Within that group, observed mean weight loss at 68 weeks reached 25.4%.

Denmark Awards DKK 15 Million Over NAION Cases

Denmark's patient compensation body on 17 November awarded payments to a total of 31 patients amounting to DKK 15 million. The cases involved suspected NAION eye disease following treatment with Wegovy or Ozempic.

Ad

Novo Nordisk Stock: New Analysis - 22 November

Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis...

Disclaimer...
en | DK0062498333 | NOVO | boerse | 70543962 |